Novo Nordisk, generational buying opportunity? Novo Nordisk is currently experiencing one of the largest drawdowns in its history, primarily triggered by a downward revision of guidance for FY25 and FY26.
Focusing strictly on technical analysis:
For the first time, the monthly 200 EMA is serving as a key support level for Novo Nordisk -
Key facts today
Novo Nordisk A/S cut its full-year sales and profit forecast for the second time in 2025. CEO Lars Fruergaard Jørgensen will resign, causing a 25% drop in pre-market stock.
Novo Nordisk's Wegovy shows a 15% weight loss, enhancing its position in the weight-loss drug market, especially as Eli Lilly's Zepbound achieves over 20% weight loss.
Hims & Hers Health ended its partnership with Novo Nordisk on August 5, 2025, after a stock price drop linked to lower revenue from its GLP-1 weight-loss drug.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
73.75 MXN
291.41 B MXN
837.97 B MXN
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG01292CB20
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
NovoNordisk, LT dirt cheap | GLP-1 a misunderstood growth marketNovo Nordisk stock has lost quite some weight since the release of Eli lilly's drug Zepbound and Mounjaro and since the rise of compounded, or generic copycat GLP-1 alternatives. The growth of the company has slown down a bit, but the overall GLP-1 market growth is still impressive and misunderstood
NVO Weekly Chart AnalysisNovo Nordisk (NVO) recently saw a sharp drop with heavy volume, signaling strong selling pressure. The chart shows a potential recovery path if the stock holds support near $47.
🔄 Possible rebound levels:
First target: $58
Mid target: $71
Final target: $82
📊 Options flow shows strong call activ
Novo Nordisk (Revised) | NVO | Long at $47.78**This is a revised analysis from February 5, 2025: I am still in that position, but added significantly more below $50**
Novo Nordisk NYSE:NVO is now trading at valuations before its release of Wegovy and Ozempic... From a technical analysis perspective, it's within my "major crash" simple mov
If you want to buy NOVO.....A follower asked for my opinion on this stock which he said many are shorting this and asks if he should be a contrarian instead.
I do not own this stock and has no intention to at this moment but just looking at the chart, here's my 2cents :
1) price has fallen by 70+% from the peak from June 202
NovoNordisk, possible rotation,safe green buy Zone after confirmNovo Nordisk got slammed after Patrick appeared in the Technical analysis and slammed the Price all the way down to goblintown. After some profit cuts and FUD in the market a possibly rotation is possible. The GLP-1 market is misunderstood. if a rotation is confirmed and some more facts will be shar
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOVOB/N is featured.
Frequently Asked Questions
The current price of NOVOB/N is 954.90 MXN — it has increased by 2.13% in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange NOVO NORDISK A/S stocks are traded under the ticker NOVOB/N.
NOVOB/N stock has fallen by −2.74% compared to the previous week, the month change is a −26.55% fall, over the last year NOVO NORDISK A/S has showed a −59.74% decrease.
We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOVOB/N price has a max estimate of 2,091.45 MXN and a min estimate of 871.44 MXN. Watch NOVOB/N chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.
NOVOB/N reached its all-time high on Jun 14, 2024 with the price of 2,708.33 MXN, and its all-time low was 948.02 MXN and was reached on Jan 24, 2022. View more price dynamics on NOVOB/N chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NOVOB/N stock is 14.29% volatile and has beta coefficient of 1.51. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?
Today NOVO NORDISK A/S has the market capitalization of 3.73 T, it has decreased by −4.93% over the last week.
Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
NOVOB/N earnings for the last quarter are 17.61 MXN per share, whereas the estimation was 17.53 MXN resulting in a 0.46% surprise. The estimated earnings for the next quarter are 17.92 MXN per share. See more details about NOVO NORDISK A/S earnings.
NOVO NORDISK A/S revenue for the last quarter amounts to 227.11 B MXN, despite the estimated figure of 227.39 B MXN. In the next quarter, revenue is expected to reach 228.28 B MXN.
NOVOB/N net income for the last quarter is 78.32 B MXN, while the quarter before that showed 86.19 B MXN of net income which accounts for −9.13% change. Track more NOVO NORDISK A/S financial stats to get the full picture.
NOVO NORDISK A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Aug 8, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is 475.05 B MXN, and current EBITDA margin is 50.95%. See more stats in NOVO NORDISK A/S financial statements.
Like other stocks, NOVOB/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO NORDISK A/S technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO NORDISK A/S stock shows the sell signal. See more of NOVO NORDISK A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.